Patents by Inventor Christopher Fraser

Christopher Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952592
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 9, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Publication number: 20240095350
    Abstract: A threat management system features a recommendation engine and an action engine. The recommendation engine is configured to (i) conduct analytics on content from the threat catalog and content from the enterprise profile to generate results that identify a plurality of threats directed to the enterprise and (ii) generate a top threat list based on the analytic results. The action engine is communicatively coupled to the recommendation engine. The action engine is configured to receive the top threat list and generate a plurality of actions corresponding to each threat of the top threat list, where each action of the plurality of actions includes information directed to operations to mitigate or neutralize a risk associated with a threat of the top threat list.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 21, 2024
    Inventors: Benjamin Withnell, Nalani Fraser, Christopher Key
  • Publication number: 20240098114
    Abstract: A computerized method features operations conducted by a security analyzer device to process incoming information to ascertain a presence of cybersecurity threats based on a top threat list provided to the security analyzer device. The top threat list includes a plurality of cybersecurity threats prioritized for an enterprise that is subscribing to a threat management system and protected by the security analyzer device. The computerized method further conducts analytics of incoming information to determine a level of correlation between at least a portion of the incoming information and any of the plurality of cybersecurity threats within the top threat lists content, and upon determining the level of correlation between the portion of the incoming information and a cybersecurity threat of the plurality of cybersecurity threats exceeding a first threshold, may conduct operations to neutralize or mitigate the cybersecurity threat.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 21, 2024
    Inventors: Benjamin Withnell, Nalani Fraser, Christopher Key
  • Publication number: 20230321224
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.
    Type: Application
    Filed: December 8, 2022
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Publication number: 20230321225
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: March 2, 2023
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Patent number: 11779641
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 10, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Publication number: 20230310593
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 5, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Patent number: 11717569
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: August 8, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
  • Publication number: 20220397097
    Abstract: The present invention relates to non-thermal renewable energy turbines (20,24,34, 38,40), in particular to the monitoring of turbine performance to identify a loss of performance indicative of faults or component degradation. The method involves comparison of measured power from a target turbine (20) with a predicted value for same turbine. The predicted value is calculated using the output from a plurality of other turbines (24,34,38,40) from an array and a predictive model including weightings for the other turbines (24, 34,38,40) based on the strength of correlation of their historical with historical data from the target turbine (20).
    Type: Application
    Filed: November 11, 2020
    Publication date: December 15, 2022
    Inventors: Christopher FRASER, Thomas Humphries, Ty Burridge-Oakland
  • Publication number: 20200238990
    Abstract: A trailer for use with a towing vehicle having a first connector. The trailer includes a connector assembly, a plurality of wheels, and a trailer assist assembly. The connector assembly includes a second connector and at least one sensor. The second connector is configured to be coupled to the first connector to thereby couple the trailer to the towing vehicle. The at least one sensor is configured to detect forces applied to at least a portion of the connector assembly. The trailer assist assembly includes a control system and at least one electric motor. The control system is configured to control operation of the at least one electric motor, receive sensor signals from the at least one sensor, and use the sensor signals to determine when to operate the at least one electric motor. The at least one electric motor is operable to drive the plurality of wheels.
    Type: Application
    Filed: July 24, 2019
    Publication date: July 30, 2020
    Inventors: Michael Ma, Christopher Fraser
  • Patent number: 10706746
    Abstract: The present invention relates to methods and systems for binary scrambling, and applications for cybersecurity technology aimed at preventing cyber-attacks.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 7, 2020
    Assignee: Polyverse Corporation
    Inventors: Alexander Gounares, Christopher Fraser
  • Publication number: 20200101154
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Publication number: 20200101155
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Publication number: 20190371209
    Abstract: The present invention relates to methods and systems for binary scrambling, and applications for cybersecurity technology aimed at preventing cyber-attacks.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 5, 2019
    Inventors: Alexander GOUNARES, Christopher FRASER
  • Patent number: 10441651
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 15, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Patent number: 10420835
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 24, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Patent number: 10004802
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 26, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Patent number: 9987354
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 5, 2018
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Publication number: 20160279234
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 29, 2016
    Applicant: SELECTA BIOSCIENCES, INC.
    Inventors: TAKASHI KEI KISHIMOTO, CHRISTOPHER FRASER, ROBERTO A. MALDONADO
  • Publication number: 20160256401
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 8, 2016
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado